MISTI
Developer of a mesh‑free, breath‑synchronised pulmonary delivery platform designed to improve consistency, particle control and real‑world usability of inhaled therapies. The platform combines high‑frequency acoustic aerosol generation, breath detection, a wearable patient interface, pre‑filled liquid cartridges and a connected digital layer to enable formulation‑conscious aerosolisation, delivery visibility and co‑development with pharmaceutical and healthcare partners. The program is at early technical and usability validation stages with a defined pathway toward regulatory translation and manufacturability.
Industries
Nr. of Employees
small (1-50)
Products
MedMisti (wearable breath‑actuated inhalation system)
A wearable mask system integrating breath detection, mesh‑free acoustic aerosol generation, pre‑filled liquid cartridges and connected data capture to simplify respiratory treatment and provide delivery visibility.
Misti
A mesh-free pulmonary drug delivery technology platform that uses high-frequency acoustic energy and breath actuation to generate controlled aerosols for inhaled therapies.
MedMisti (wearable breath‑actuated inhalation system)
A wearable mask system integrating breath detection, mesh‑free acoustic aerosol generation, pre‑filled liquid cartridges and connected data capture to simplify respiratory treatment and provide delivery visibility.
Misti
A mesh-free pulmonary drug delivery technology platform that uses high-frequency acoustic energy and breath actuation to generate controlled aerosols for inhaled therapies.
Services
Benchmarking aerosol output, particle size tuning and formulation compatibility to assess suitability of inhaled therapies for acoustic aerosolisation.
User testing and human factors evaluation with patient and caregiver cohorts to guide ergonomic design, onboarding and app guidance.
Early regulatory strategy, risk management and quality‑system planning to support clinical translation and market access.
Design for manufacture, pilot production planning and supply‑chain partnership for device and cartridge scale‑up.
Benchmarking aerosol output, particle size tuning and formulation compatibility to assess suitability of inhaled therapies for acoustic aerosolisation.
User testing and human factors evaluation with patient and caregiver cohorts to guide ergonomic design, onboarding and app guidance.
Early regulatory strategy, risk management and quality‑system planning to support clinical translation and market access.
Design for manufacture, pilot production planning and supply‑chain partnership for device and cartridge scale‑up.
Expertise Areas
- Pulmonary drug delivery platform development
- Acoustofluidics and aerosol science
- Device usability and human factors
- Connected health and treatment telemetry
Key Technologies
- Acoustofluidic (surface acoustic wave) aerosol generation
- Breath‑actuated delivery sensors
- Wearable mask patient interface
- Pre‑filled liquid cartridge systems
News & Updates
Platform development is grounded in over 10 years of academic and peer‑reviewed work in surface acoustic wave aerosolisation and acoustofluidics.
Internal aerosol testing reports MMAD of approximately 2–4 µm, GSD ~1.1 and fine particle fraction >90% under defined conditions.
University of Melbourne Digital Simulation Lab pre‑pilot testing with caregivers and children (n=15) reported high preference versus spacer and positive usability metrics (e.g., 92% preferred MedMisti over a spacer).
Initial in‑vitro studies indicate acoustic aerosolisation did not cause statistically meaningful loss of biological activity for lipid nanoparticle mRNA constructs.
Platform development is grounded in over 10 years of academic and peer‑reviewed work in surface acoustic wave aerosolisation and acoustofluidics.
Internal aerosol testing reports MMAD of approximately 2–4 µm, GSD ~1.1 and fine particle fraction >90% under defined conditions.
University of Melbourne Digital Simulation Lab pre‑pilot testing with caregivers and children (n=15) reported high preference versus spacer and positive usability metrics (e.g., 92% preferred MedMisti over a spacer).
Initial in‑vitro studies indicate acoustic aerosolisation did not cause statistically meaningful loss of biological activity for lipid nanoparticle mRNA constructs.